HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 口头报告论文：#LCSM 非转移性 🔥生物标志物与 KEYNOTE-671 III期研究中围手术期 Pembrolizumab（Pembro）联合新辅助化疗（Chemo）治疗早期非小细胞肺癌（NSCLC）的疗效之间的关联 🎙️ @marinagarassino 🔢2519O 🎯更高的 TMB 与 Pembro 治疗下更好的 EFS（p=0.000164）和 OS（p=0.005）相关 🎯无论 T-cell-inflamed GEP、TMB 或 KRAS 状态如何，Pembro 相比 Chemo 的获益均一致 ☑️NCT03425643 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC
热度 3 · 3 赞 · 0 回复 · 0 转发
会议摘要
NCT03425643NCT03425643按 - **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) 对上
- **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)读摘要原文 →来源：HHorinouchi · x.com